A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Active, not recruiting · Phase 2 · NCT06465329
Conditions: Non Small Cell Lung Cancer, NSCLC
At a glance
- Research payments reported, 2025
- $766,149
- U.S. investigators named
- 12
- Sites paid
- 10
- Planned or actual enrollment
- 184
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Cemiplimab (drug), Platinum-based chemotherapy (drug), Marlotamig (drug), REGN10597 (drug)
- Dates
- Started 2024-11-18; completion 2034-12-27
- Results posted
- Not yet
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer (NSCLC) for whom surgery is planned, in the resectable NSCLC portion. The aim of the resectable NSCLC portion is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. For each investigational arm, the available data will be reviewed to decide whether safety testing with chemotherapy is needed before moving the treatment combination to the main resectable NSCLC portion of the study. If safety testing with chemotherapy is required, adul…
From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $766,149 in research payments for this study in 2025 (168 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Misako Nagasaka, MD Hematology & Oncology · Orange, CA
- Ira A. Oliff, MD Hematology & Oncology · Skokie, IL
- Tarik H. Hadid, MD Hematology & Oncology · Warren, MI
- Joseph Merriman, M.D. Hematology & Oncology · Charlotte, NC
- David B. Berkheim Cardiothoracic Surgery · Omaha, NE
- Karim R. Saab, M.D. Hematology & Oncology · Morristown, NJ
- Christopher G. Azzoli, MD Medical Oncology · New York, NY
- Jayadev R. Mettu, M.B.B.S Hematology & Oncology · Fairfield, OH
- Rachel E. Sanborn, MD Medical Oncology · Portland, OR
- Ardy Davarifar, MD/PHD Hematology & Oncology · Knoxville, TN
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Jerome H. Goldschmidt JR., M.D. Hematology & Oncology · Christiansburg, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University Health System, Inc, TN $223,769
- Karmanos Cancer Center, MI $138,537
- Sarah Cannon Research Institute LLC $120,094
- Providence Portland Medical Center, OR $88,008
- Uci Health - Fountain Valley, CA $52,182
- Rhode Island Hospital, RI $37,840
- Morristown Medical Center, NJ $33,360
- Orchard Healthcare Research Inc $25,021
- Oneoncology Research Network LLC $22,500
- Unehealth $22,438
- $2,400
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.